Savara Pharmaceuticals

Savara is a clinical stage pharmaceutical company focused on developing and commercializing therapies for patients with respiratory diseases that are inadequately treated with currently available medicines.

The company’s lead therapy is dry powder inhalable form of an antibiotic for the treatment of MRSA in CF patients and other lung compromised patients. This therapy has successfully completed dosing of volunteers in a  Phase 1 trial and is currently enrolling in a lung pharmacokinetics study in cystic fibrosis patients.

In addition, Savara is applying its proprietary formulation technologies to enable and improve the pulmonary delivery of proven drugs for internal pipeline development and commercial partners.